Taysha Gene Therapies (TSHA) Gains from Investment Securities (2023 - 2025)

Taysha Gene Therapies has reported Gains from Investment Securities for 3 years, with the latest figure at $736000.0 in Q4 2025.

• Quarterly Gains from Investment Securities rose 986.75% year-over-year to $736000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (up 7593.75% YoY) and the FY2025 annual result came in at $1.2 million, up 7593.75% from the prior year.
• Gains from Investment Securities advanced to $736000.0 in Q4 2025 per TSHA's latest filing, from $292000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $736000.0 in Q4 2025 and troughed at -$66.0 million in Q4 2023.
• A 3-year average of -$7.2 million and a median of -$75000.0 in 2024 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 986.75% in 2025, down 130.27% in 2025.
• Over 3 years, Gains from Investment Securities stood at -$66.0 million in 2023, then surged by 99.87% to -$83000.0 in 2024, then soared by 986.75% to $736000.0 in 2025.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $736000.0, $292000.0, and $273000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.